Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial

Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial

Introduction Hepatitis B surface antigen (HBsAg) clearance is the treatment goal for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). However, its rate is extremely low with nucleoside (acid) analogues (NAs) monotherapy. Peginterferon could enhance HBsAg clearance. Thi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infectious diseases and therapy 2021-12, Vol.10 (4), p.2259-2270
Hauptverfasser: Chen, Jun, Qi, Min, Fan, Xue-Gong, Hu, Xing-Wang, Liao, Cheng-Jin, Long, Li-Yuan, Zhao, Xiao-Ting, Tan, Min, Li, Hai-Fu, Chen, Ruo-Chan, Huang, Ze-Bing, Huang, Yan
Format: Artikel
Sprache:eng
Schlagworte:
Adefovir dipivoxil
Antigens
Clinical trials
Deoxyribonucleic acid
DNA
Drug therapy
Hepatitis
Hepatitis B
Infectious Diseases
Interferon
Internal Medicine
Medicine
Medicine & Public Health
Original Research
Telbivudine
Viral antigens
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Hepatitis B surface antigen (HBsAg) clearance is the treatment goal for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). However, its rate is extremely low with nucleoside (acid) analogues (NAs) monotherapy. Peginterferon could enhance HBsAg clearance. This study aimed to evaluate the efficacy of peginterferon alfa-2b (PegIFNα-2b) in NAs-experienced patients with CHB with negative HBeAg and low HBsAg level. Methods HBeAg-negative patients with CHB who had received NAs therapy over 24 weeks with HBsAg 
ISSN:2193-8229
2193-6382
DOI:10.1007/s40121-021-00497-5